Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0242339 (
dyslipidemia
)
13,927
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Polyunsaturated fatty acids (PUFA) correlate with risk of
dyslipidemia
and cardiovascular diseases. Fatty acid desaturase (
FADS
) single nucleotide polymorphisms (SNPs) modulate circulating PUFA concentrations. This study examined influence of
FADS1
and
FADS2
genetic variants on desaturase activities and blood lipid concentrations in type 2 diabetes patients, and further assessed their interrelationships. Selected SNPs (
FADS1
: rs174547, rs174548, rs174550;
FADS2
: rs174575, rs174576, rs174583, rs498793 and rs2727270) were genotyped in 820 type 2 diabetes patients and compared with those reported in the HapMap. Patient subgroups (
n
= 176) without taking lipid-lowering medicine were studied to assess influence of tag SNPs including rs174547, rs174575, rs498793 and rs2727270 on delta-5 desaturase (D5D: 20:4 (n-6)/20:3 (n-6)) and delta-6 desaturase (D6D:18:3 (n-6)/18:2 (n-6)) activities, and blood lipids.
FADS1
rs174547 TT/TC/CC and
FADS2
rs2727270 CC/CT/TT were significantly (
p
for trend < 0.05) associated with reduced HDL-C, D5D and D6D activities. Upon adjustment for confounders, D5D (
p
= 0.006) correlated significantly and D6D marginally (
p
= 0.07) correlated with increased HDL-C levels, whereas rs174547 and rs2727270 polymorphisms were not associated. D6D andD5D activities may play a role in modulating HDL-C levels in type 2 diabetes. Future studies with larger sample sizes are needed to investigate how
FADS
genetic variations interact with desaturase activities or PUFAs in the metabolism of lipoproteins in diabetic patients.
...
PMID:FADS Gene Polymorphisms, Fatty Acid Desaturase Activities, and HDL-C in Type 2 Diabetes. 2855 39